spacer
home > pmps > spring 2017 > easy access
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Easy Access

Times have changed dramatically in the past 10 years, with external cost pressure, patent losses, dried-up R&D pipelines and the rise of biosimilars forcing Big Pharma to rethink its business models. All of a sudden, the cost of packaging drugs can make a telling difference to the bottom line, or even mean the difference between winning a tender or not.

All of this comes in an environment where patients are hoping for greater protection from external contamination, counterfeits and their children accessing dangerous drugs, and payers are expecting the industry to demonstrate the effectiveness of their products. But how can pharmaceutical companies balance the conflicting needs of lower cost and higher protection?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Colin Reed is Marketing and Strategy Director for Amcor Flexibles Global Pharma and Medical EMEA businesses. He has 19 years of experience in pharmaceutical packaging and has held previous leadership positions in operations and marketing, including managing businesses in the Asia- Pacific region. Colin holds a Bachelor of Engineering degree and an MBA from Aston University, UK.

Greg Rosati is currently the Healthcare Marketing Director for Amcor Rigid Plastics. He has 24 years of packaging experience including 15 in healthcare and has held various leadership roles in product development, sales, marketing and quality systems. Greg holds a BS from Michigan State University, US.
spacer
Colin Reed
spacer
spacer
spacer
Greg Rosati
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Saneca Pharma strengthens senior team

Slovakia-based CDMO adds senior talent to its team to position the company for continued growth
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

3D Cell Culture 2018

21-22 February 2018, Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement